People: New Executive Director At FASEB Seeks Societies' Consensus On Policy Issues

The Federation of American Societies for Experimental Biology, recently redefining its organizational goals, has a new executive director to guide the organization in achieving these objectives. Michael Jackson, a physiologist who was dean of research at George Washington University Medical Center in Washington, D.C., takes the FASEB post this week. At a retreat in Williamsburg, Va., last year, representatives of the 31,000-member orgaanization decided that FASEB's seven constituent societies

Written byKen Kalfus
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Federation of American Societies for Experimental Biology, recently redefining its organizational goals, has a new executive director to guide the organization in achieving these objectives. Michael Jackson, a physiologist who was dean of research at George Washington University Medical Center in Washington, D.C., takes the FASEB post this week.

At a retreat in Williamsburg, Va., last year, representatives of the 31,000-member orgaanization decided that FASEB's seven constituent societies should speak with a more unified voice on national science issues. Jackson, now chosen to implement the decision, says his focus will be "to enhance the role of the federation in developing consensus and access."

One of Jackson's principal aims is to give bench scientists more of a voice. "Our concern is that [national policy] decisions are not adequately representative of practicing scientists," he says.

Jackson cites low levels of funding, the need for improvement in laboratory facilities, and the training ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies